JTK 652

Drug Profile

JTK 652

Alternative Names: JTK-652

Latest Information Update: 29 Apr 2009

Price : $50

At a glance

  • Originator Japan Tobacco
  • Class Antivirals
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 26 Apr 2009 Final adverse events and efficacy data from a phase I trial in HCV infections presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL-2009)
  • 30 Jun 2008 Discontinued - Phase-I for Hepatitis C (PO)
  • 31 Oct 2007 Phase-I clinical trials in Hepatitis C treatment (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top